Medivo Study Supports Link Between Diabetes and Fatty Liver Disease

Share Article

Analysis of over 200,000 patients has been selected for a Guided Poster Tour at the upcoming AACE Annual Meeting

News Image
Medivo strives each and every day to discover new insights that can further our mission to unlock the power of lab data to improve health.

Medivo, Inc., a leader in lab data analytics, will be presenting an abstract entitled “ELEVATED AST AND ALT RESULTS AND AN AST/ALT RATIO BETWEEN 0.7 AND 1.0 LINKED TO AN INCREASED RISK OF NASH IN PATIENTS WITH DIABETES” at the The American Association of Clinical Endocrinologists (AACE) 24th Annual Scientific & Clinical Congress in Nashville, TN, May 13-17, 2015.

The study was conducted by Medivo’s Clinical Affairs and Analytics team members Carol Smyth, MB; Jason Bhan, MD; Tatiana Sorokina, MSc; and Mauricio Alarcon, BSc, along with Timothy S. Bailey, MD, FACE from the AMCR Institute in Escondido, CA. The poster has been selected to be presented as part of the Diabetes Mellitus/Prediabetes Poster Tour beginning at 10am on Friday, May 15, 2015. Co-author Carol Smyth will be on hand to present and answer questions.

About the study: Nonalcoholic steatohepatitis (NASH) is thought to affect 5% of Americans, with an even higher prevalence in those with diabetes (DM). There is no known lab test currently available to screen for NASH. The purpose of the analysis was to uncover a screening test for NASH by analyzing the lab test results of more than 200,000 patients in the Medivo nationwide lab test database.

According to Dr. Bhan, Medivo’s Chief Medical Officer, “The ability to study patients on such a large scale is incredibly exciting to the research community. Medivo strives each and every day to discover new insights that can further our mission to unlock the power of lab data to improve health.”

Noted Dr. Bailey, “Our analysis suggested that elevated AST and ALT lab test results, and an AST/ALT ratio between 0.7 - 1.0 are associated with NASH or risk for NASH. We also found a significantly higher risk of NASH in patients with DM compared to those without DM. These findings mean that with further study, we may be able to use these commonly run liver function tests to screen our diabetic patients for NASH.”

The poster is available for viewing online in the Medivo Resource Library. Questions about this study should be directed to Carol Smyth at csmyth(at)medivo(dot)com.

About Medivo
Medivo is a health data analytics company that unlocks the power of lab data to improve health. Medivo is the largest source of lab data in the U.S., with access to over 150M patients through its nationwide network of partner labs. Medivo analyzes large, de-identified data sets and shares its findings with the medical community at large, as well as with its life science, payer and lab partners, to ensure that appropriate available treatments are provided to patients sooner. Founded in 2010 by healthcare entrepreneurs, Medivo’s investors include Safeguard Scientifics, Inc. (NYSE:SFE) and Merck Global Health Innovation Fund (GHIF). For more information, visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Allison Keeley
+1 (917) 945-8502
Email >
Visit website